Robert Hillman
Fondateur chez CeleCor Therapeutics, Inc.
Profil
Robert S.
Hillman was the founder of Accumetrics, Inc. (founded in 1997) where he held the title of Director from 2009 to 2010.
Dr. Hillman is also the founder of Angiosyn, Inc., ActivX Biosciences, Inc., CeleCor Therapeutics, Inc. Dr. Hillman's former jobs include being a Principal at Syva Co., Gensia Pharmaceuticals, Inc., and.
Biotrack, Inc. Dr. Hillman received his undergraduate degree from Stanford University, his graduate degree from Massachusetts Institute of Technology, and his doctorate from Swiss Federal Institute of Technology.
Postes actifs de Robert Hillman
| Sociétés | Poste | Début |
|---|---|---|
CeleCor Therapeutics, Inc.
 CeleCor Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services CeleCor Therapeutics, Inc. engages in the development of RUC-4, a novel small molecule platelet inhibitor of the platelet aIIbß3 receptor. Its product is design to administered subcutaneously via auto-injector to facilitate its use as the first point of medical contact in order to improve the treatment of serious heart attacks. The company was founded by Barry S. Collein, Robert S. Hillman and Andreas Ritzi and is headquartered in San Diego, CA. | Fondateur | - |
Anciens postes connus de Robert Hillman
| Sociétés | Poste | Fin |
|---|---|---|
Angiosyn, Inc.
 Angiosyn, Inc. Pharmaceuticals: OtherHealth Technology Angiosyn, Inc. develops pharmaceutical products for controlling angiogenesis | Fondateur | 11/02/2009 |
| Syva Co. | Corporate Officer/Principal | - |
| Biotrack, Inc. | Corporate Officer/Principal | - |
Gensia Pharmaceuticals, Inc.
 Gensia Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Gensia Pharmaceuticals, Inc. manufactures and distributes pharmaceutical products for cardiovascular diseases. The company is based in San Diego, CA and has subsidiaries in the United States. The company was founded by Robert L. Engler, Paul K. Laikind. | Corporate Officer/Principal | - |
ActivX Biosciences, Inc.
 ActivX Biosciences, Inc. Pharmaceuticals: MajorHealth Technology ActivX Biosciences, Inc. develops pharmaceutical products. It discovers and develops small molecule drugs for major unmet medical needs. The company was founded in 2000 and is located in La Jolla, CA | Fondateur | - |
Formation de Robert Hillman
| Stanford University | Undergraduate Degree |
| Massachusetts Institute of Technology | Graduate Degree |
| Swiss Federal Institute of Technology | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 7 |
|---|---|
Accumetrics, Inc.
 Accumetrics, Inc. Medical SpecialtiesHealth Technology Accumetrics, Inc. developed, manufactured and marketed diagnostic testing and measurement instruments. The company was founded by Dennis Durbin and Robert S. Hillman in 1997 and was headquartered in San Diego, CA. | Health Technology |
Angiosyn, Inc.
Angiosyn, Inc. Pharmaceuticals: OtherHealth Technology Angiosyn, Inc. develops pharmaceutical products for controlling angiogenesis | Health Technology |
ActivX Biosciences, Inc.
ActivX Biosciences, Inc. Pharmaceuticals: MajorHealth Technology ActivX Biosciences, Inc. develops pharmaceutical products. It discovers and develops small molecule drugs for major unmet medical needs. The company was founded in 2000 and is located in La Jolla, CA | Health Technology |
Gensia Pharmaceuticals, Inc.
Gensia Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Gensia Pharmaceuticals, Inc. manufactures and distributes pharmaceutical products for cardiovascular diseases. The company is based in San Diego, CA and has subsidiaries in the United States. The company was founded by Robert L. Engler, Paul K. Laikind. | Health Technology |
| Biotrack, Inc. | |
| Syva Co. | |
CeleCor Therapeutics, Inc.
CeleCor Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services CeleCor Therapeutics, Inc. engages in the development of RUC-4, a novel small molecule platelet inhibitor of the platelet aIIbß3 receptor. Its product is design to administered subcutaneously via auto-injector to facilitate its use as the first point of medical contact in order to improve the treatment of serious heart attacks. The company was founded by Barry S. Collein, Robert S. Hillman and Andreas Ritzi and is headquartered in San Diego, CA. | Commercial Services |
